Participation in upcoming investor conferences

Oxford Nanopore Technologies plc
13 November 2023
 

 

Oxford Nanopore Technologies plc

Oxford Nanopore to participate in upcoming investor conferences

 

13 November 2023

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that management will be participating in the following upcoming investor conferences:

 

·      Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, 16 November 2023 in New York, USA

·      J.P. Morgan UK Leaders Conference on Tuesday, 21 November 2023 in London, UK

·      Berenberg European Conference on Thursday, 7 December 2023 in Surrey, UK

 

Gordon Sanghera, Chief Executive Officer, will participate in an analyst led fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, 16 November at 11:00am ET/ 4:00pm GMT. A live webcast of the event can be accessed at the company's investor relations page at: https://nanoporetech.com/about-us/investors/reports. A replay will be available via the same link following the event.

 

 

[ENDS]

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:          ir@nanoporetech.com

Media:              media@nanoporetech.com

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

 

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA.  The technology is used in more than 120 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.  Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. 

For more information please visit: www.nanoporetech.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings